# Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

> **NIH NIH U54** · EMORY UNIVERSITY · 2022 · $359,168

## Abstract

Abstract
COVID-19 infection is greatly heterogenous. Individuals with underlying immune dysregulation,
will have abnormal responses to COVID-19, thereby accounting for different short-term outcomes
and memory formation. Specifically, emerging evidence indicates poor outcomes in autoimmune
and cancer patients. We propose that autoimmune patients and severe COVID-19 infection will
share an exacerbated pathological response while cancer patients with disease-associated or
treatment-induced immune deficiency, will fail to mount a protective anti-viral response. Here, we
shall interrogate the effector B cell response to SARS-CoV-2 to identify determinants of protective
and pathogenic responses in HC and autoimmune subjects.

## Key facts

- **NIH application ID:** 10680631
- **Project number:** 4U54CA260563-02
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Ignacio E. Sanz
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $359,168
- **Award type:** 4N
- **Project period:** 2020-09-30 → 2025-03-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10680631

## Citation

> US National Institutes of Health, RePORTER application 10680631, Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity (4U54CA260563-02). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10680631. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*